Biotech firm Roivant said its immune-modifying drug brepocitinib outperformed a placebo in treating the skin condition ...

The FDA's crackdown on drug advertising is unprecedented, but some experts questioned whether the agency has the staff to ...

Several years ago, the late Sen. Orrin Hatch (R-Utah) and I came together to begin the transformation of Medicare, shifting ...

The Black in Neuro conference was both a victory lap marking the organization’s growth and a sober assessment of the ...

U.K.-based drugmaker GSK said it planned to invest $30 billion in the U.S. over five years, an announcement timed to this ...

The Centers for Disease Control and Prevention has revoked permission for employees with disabilities to work from home, at ...

WASHINGTON — House Republicans on Tuesday introduced a bill to fund the government at current levels until Nov. 21. It would ...

Casey Means, nominated for surgeon general, earned hundreds of thousands of dollars promoting supplements, per new financial ...

In today's Pharmalittle roundup, we're reading about Congress eyeing a Trump drug pricing plan, questions on a Sarepta drug, ...

Good morning. It seems that President Trump’s plan to address U.S. drug prices isn’t going away any time soon. Read on to see ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

WellSpan health and General Catalyst venture HATCo are partnering to develop new health tech solutions, some of which may ...